Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.
The Ewha Medical Journal
Ewha Womans University School of Medicine

Ewha Med J 1997; 20(2):145-149

pISSN: 1598-7450

DOI: https://doi.org/10.12771/emj.1997.20.2.145

Case Report

A Case of Ticlopidine-Induced Cholastatic Jaundice

Ka Eun Woo, Hong Kun Cho, Gil Ja Shin

Copyright ⓒ 1997. Ewha Womans University School of Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published Online: Jul 24, 2015

Abstract

Ticlopidine, a platelet aggregation inhibitor, is widely used in the secondary prevention of stroke and previous manifestation of peripheral arterial occlusive disease, Ticlopidine is also used to prevent myocardial infarction and post-stenting occlusion after intracoronary stent implantation. The exact mechanism of action of ticlopidine is unclear, but likely involves the inhibition of platelet activity by the suppression of adenosine diphosphate-induced patelet aggregation. The most common adverse effects are gastrointestinal problems, skin reactions, and hematologist changes. The adverse hepatic effects are not frequent(4% in different series).

We experienced a case of ticlopidine-induced cholastatic jaundice, and report with review of literatures.

Keywords: Ticlopidine(Ticlid®); Cholastatic jaundice; Acute myocardial infarction